Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab

NCT05002998 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05002998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05002998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
September 16, 2021
Completion date
December 19, 2025
Enrollment
313 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease